Alnylam at Morgan Stanley conference: ttr growth offsets guidance trim

Alnylam cut 2025 TTR-franchise guidance by $200 million at the midpoint to $4.2-$4.5 billion, citing normalization of second-line demand and expected gradual net-price erosion. The reduction contrasts with strong AMVUTTRA momentum: the drug generated $1 billion in Q2 2025 revenue only four months after its TTR-cardiomyopathy approval, while Alnylam reported $4.8 billion of trailing-12-month revenue as of Q2 2026, up 95% year over year. Management highlighted more than 50% share among AMVUTTRA prescribers, an estimated 80% of TTR patients still undiagnosed or untreated, and pipeline catalysts including Huntington's Phase 1 data in October 2025 and obesity proof-of-concept data later in 2025.

Analysis

The key underwriting change is not the modest revenue reset itself but the evidence that early conversion dynamics cannot be annualized. ALNY now needs diagnosis creation and prescriber expansion—not switch demand—to sustain growth, making sales-force productivity, payer persistence and net-price realization the relevant quarterly KPIs. That shifts the equity from a clean penetration story toward a multiple-sensitive execution story; even small misses in treated-patient growth could matter disproportionately if consensus still embeds a steep adoption curve.

Competitive risk is asymmetric. IONS's eplontersen setback likely improves ALNY's near-term field position, but it also gives payers a reason to demand stronger evidence before reimbursing premium silencing therapy broadly, especially in earlier-stage patients. PFE's eventual tafamidis genericization is not simply a future pricing threat: cheaper stabilizer access could expand diagnosis and combination use, but it could also cap ALNY's net price and make monotherapy share harder to defend.

The article's timeline is internally stale and inconsistent with its stated date, so the cited pipeline events and regulatory timing cannot be traded without verification. Near term, the November 340B outcome is the cleaner catalyst: adverse implementation would pressure gross-to-net and site-of-care economics before it necessarily affects volume. Over 6-18 months, the more consequential question is whether international reimbursement converts into profitable volume rather than lower-price revenue that dilutes franchise margins.

Contrarian view: the selloff may already discount a one-time launch normalization, but the market could still be underpricing the operational cost of finding undiagnosed patients. Management's market-share and physician-survey claims are not independent evidence of durable formulary preference; new-start share, discontinuation rates, realized net price and quarterly patient adds should determine whether this is a buyable reset or the first of several estimate reductions.

Key Decisions for Investors

• Keep ALNY on watch rather than add before independently verifying current guidance, pipeline calendars and the 340B rule status; the source-date discrepancy makes event timing unreliable. Upgrade only if the next reported quarter shows treated-patient growth offsetting net-price erosion and management holds or raises forward franchise guidance.
• If verified 340B policy is unresolved, consider a defined-risk ALNY put spread spanning the decision and next earnings rather than outright short exposure. The thesis is gross-to-net and channel-risk repricing; invalidate if management quantifies immaterial impact and maintains net-price and margin guidance.
• For a 3-6 month relative-value expression after data verification, prefer long ALNY / short IONS only if ALNY sustains new-start share while IONS faces incremental cardiomyopathy commercial de-risking. Exit on evidence of meaningful eplontersen reimbursement traction, a material ALNY price concession, or narrowing physician preference indicators.
• Do not use QURE as a mechanical hedge for ALNY's Huntington's program: any readthrough depends on target biology, CNS delivery, durability and safety, not merely the shared indication. Treat verified Huntington's data as a volatility alert for both names, with position sizing reduced ahead of data rather than assuming directional correlation.